Capital Research Global Investors Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Capital Research Global Investors raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,749 shares of the biopharmaceutical company’s stock after purchasing an additional 3,635 shares during the quarter. Capital Research Global Investors’ holdings in Regeneron Pharmaceuticals were worth $59,455,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of REGN. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. Traub Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $38,000. Finally, Berbice Capital Management LLC raised its position in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EU regulatory progress for Dupixent: reporting notes that the CHMP gave a positive opinion supporting Dupixent for children aged 2–11 with chronic spontaneous urticaria in the EU — a label expansion that could help sustain Dupixent revenue momentum in Europe. Sanofi’s EU Drug Wins Contrast With Weak Share Momentum And Valuation Gap
• Positive Sentiment: Corporate goodwill and brand visibility from science outreach: Regeneron’s sponsorship of the Regeneron Science Talent Search (awarding more than $1.8M) is positive for reputation and stakeholder relations — a modest supportive factor for investor sentiment. Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists
• Neutral Sentiment: Management presentations (Leerink, Barclays): Regeneron posted transcripts from recent conferences (Leerink, Barclays). These maintenances of visibility and messaging help keep investors informed about pipeline priorities (Dupixent, Libtayo, other assets) but did not introduce major new catalysts. Regeneron Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Barclays conference transcript provides additional management commentary but no headline surprises; useful for modeling guidance and pipeline timing. Regeneron Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Sector roundup context: broader health‑care coverage (eczema treatments, Roche pipeline) underscores competitive dynamics in dermatology and immunology — contextually relevant to Dupixent but not an immediate Regeneron‑specific catalyst. Health Care Roundup: Market Talk
• Negative Sentiment: Analyst view warns of limited near‑term upside: a recent analysis argues REGN is “fairly valued” after a strong run and expects near‑term sideways trading because there are few immediate new revenue drivers; it also notes declining Eylea/Eylea HD sales that will need to be offset by Dupixent and future pipeline contributions. That view can cap short‑term upside despite long‑term confidence in Dupixent. Regeneron: Fairly Valued Now After A Stellar Upswing

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on REGN. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Scotiabank raised their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Finally, HSBC began coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $802.27.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last three months. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of REGN opened at $774.66 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $81.90 billion, a P/E ratio of 18.64, a PEG ratio of 2.07 and a beta of 0.41. The firm’s 50-day moving average is $770.85 and its two-hundred day moving average is $692.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $12.07 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.